FOR IMMEDIATE RELEASE

AUTOIMMUNE INC. REPORTS 2002 THIRD QUARTER FINANCIAL RESULTS

Pasadena, California, November 6, 2002 – AutoImmune Inc. (Nasdaq: AIMM) today reported a net loss of $0.25 million, or $0.01 per share basic and diluted, for the three months ended September 30, 2002, compared with net income of $1.14 million, or $0.07 per share basic and diluted, for the three months ended September 30, 2001. For the nine months ended September 30, 2002, the net loss was $0.64 million, or $0.04 per share basic and diluted, compared with net income of $0.95 million, or $0.06 per share basic and $0.05 diluted, for the nine months ended September 30, 2001. The results for the three-month and nine-month periods ended September 30, 2001 reflect receipt of a payment from a subsidiary of Elan Corporation plc for its purchase of Autoimmune’s rights to certain patent applications. In addition, results for all periods reflect the continued receipt of payments from BioMS Medical Corporation (“BioMS”) and a reduction in interest income due to a lower average return on investment. As of September 30, 2002, the Company reported $10.2 million in cash and marketable securities as compared to $11.0 in cash and marketable securities as of September 30, 2001.

Robert C. Bishop, Ph.D., Chairman of the Board and Chief Executive Officer stated “This past quarter AutoImmune announced the formation of Colloral LLC, a joint venture with Deseret Laboratories International for the manufacture, marketing and sale of Colloral™, a product for nutritional support of patients with rheumatoid arthritis. We hope to introduce the product early in the first quarter of next year and look forward to beginning the next stage of corporate development. AutoImmune has structured the relationship with Deseret in a manner that allows us to continue conserving financial resources while pursuing additional outlicensing opportunities and waiting for results from externally funded clinical trials.”

BioMS has confirmed that it anticipates starting an advanced phase clinical trial during the first quarter of 2003 on its MBP8298 treatment for chronic progressive multiple sclerosis, which utilizes intellectual property rights exclusively licensed from AutoImmune. Teva Pharmaceutical Industries, Ltd., is conducting additional pre-clinical and clinical pharmacology studies on an oral formulation of COPAXONE® (glatiramer acetate), a product for the treatment of multiple sclerosis, which utilizes intellectual property rights exclusively licensed from AutoImmune. Recruitment has been ended for the oral insulin arm of the NIH sponsored diabetes prevention trial (DPT-1), which is testing a therapeutic method covered by AutoImmune’s intellectual property, and preliminary results are expected toward the middle of next year.

AutoImmune is a biopharmaceutical company involved in the development of a new class of mucosally administered therapies for the treatment of autoimmune and cell-mediated inflammatory diseases and conditions.

This release contains forward-looking statements which involve risks and uncertainties. The Company’s actual results may differ significantly from results discussed in the forward-looking statements due to a number of important factors, including, but not limited to the uncertainties of clinical trial results, the Company’s dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission in the section “Business-Factors to be Considered.” The discussion in the Annual Report on Form 10-K is hereby referenced into this release.

- Financial Chart Follows -